{"collection_id":"ispy1","collection_name":"ISPY1","cancer_types":"Breast Cancer","tumor_locations":"Breast","species":"Human","subjects":222,"supporting_data":"Clinical, Image Analyses","description":"ISPY1/ACRIN 6657 was designed as a prospective study to test MRI for ability to predict response to\ntreatment and risk-of-recurrence in patients with stage 2 or 3 breast cancer receiving neoadjuvant\nchemotherapy (NACT). ACRIN 6657 was conducted as a companion study to CALGB 150007, a correlative\nscience study evaluating tissue-based biomarkers in the setting of neoadjuvant treatment of breast\ncancer. Collectively, CALGB 150007 and ACRIN 6657 formed the basis of the multicenter Investigation\nof Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis (I-SPY\nTRIAL) breast cancer trial, a study of imaging and tissue-based biomarkers for predicting pathologic\ncomplete response (pCR) and recurrence-free survival (RFS).\nThe collection consists of 847 MR studies from 222 subjects.\nPlease see the ISPY1 (http://doi.org/10.7937/K9/TCIA.2016.HdHpgJLK) page to learn more about the\nimages and to obtain any supporting metadata for this collection.","patients":222,"studies":847,"series":9877,"instances":388525,"size_TB":0.078,"modalities":["MR","SEG","SR"],"licenses":[{"license_short_name":"CC BY 3.0","series":9877,"size_TB":0.078}]}